Stocks
ImmunoGen Financial Statements (IMGN) |
||||||||||
| ImmunoGensmart-lab.ru | % | 2018 | 2019 | 2020 | 2021 | 2022 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 01.03.2019 | 11.03.2020 | 01.03.2021 | 28.02.2022 | 01.03.2023 | 02.11.2023 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 53.8 | 82.3 | 132.3 | 108.8 | 108.8 | 393.2 | |||
| Operating Income, bln rub | -160.5 | -92.2 | -135.5 | -220.9 | -220.9 | 43.5 | ||||
| EBITDA, bln rub | ? | -153.5 | -65.7 | -19.7 | -217.5 | -217.5 | 56.7 | |||
| Net profit, bln rub | ? | -167.9 | -122.1 | -66.7 | -222.9 | -222.9 | 53.0 | |||
| OCF, bln rub | ? | -166.4 | -88.4 | -78.6 | -229.8 | -229.8 | -130.7 | |||
| CAPEX, bln rub | ? | 5.25 | 2.85 | 0.917 | 1.36 | 1.36 | 1.51 | |||
| FCF, bln rub | ? | -171.7 | -91.2 | -79.5 | -231.2 | -231.2 | -132.2 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 210.6 | 153.0 | 153.2 | 329.5 | 329.5 | 343.5 | ||||
| Cost of production, bln rub | 173.9 | 114.5 | 114.6 | 0.176 | 0.176 | 6.13 | ||||
| R&D, bln rub | 173.9 | 114.5 | 114.6 | 213.4 | 213.4 | 195.3 | ||||
| Interest expenses, bln rub | 10.7 | 17.0 | 23.2 | 4.17 | 4.17 | 4.27 | ||||
| Assets, bln rub | 295.8 | 235.7 | 355.1 | 348.9 | 348.9 | 822.1 | ||||
| Net Assets, bln rub | ? | 11.9 | -76.1 | 89.6 | 155.8 | 155.8 | 561.6 | |||
| Debt, bln rub | 2.06 | 26.8 | 23.9 | 15.2 | 15.2 | 72.1 | ||||
| Cash, bln rub | 262.3 | 176.2 | 293.9 | 275.1 | 275.1 | 605.5 | ||||
| Net debt, bln rub | -260.2 | -149.4 | -270.0 | -259.9 | -259.9 | -533.4 | ||||
| Ordinary share price, rub | 4.80 | 5.11 | 6.45 | 7.42 | 4.96 | 5.83 | ||||
| Number of ordinary shares, mln | 139.9 | 148.3 | 176.2 | 253.6 | 253.3 | 273.3 | ||||
| Market cap, bln rub | 672 | 758 | 1 136 | 1 882 | 1 257 | 1 594 | ||||
| EV, bln rub | ? | 412 | 608 | 866 | 1 622 | 997 | 1 060 | |||
| Book value, bln rub | 12 | -76 | 90 | 156 | 156 | 562 | ||||
| EPS, rub | ? | -1.20 | -0.82 | -0.38 | -0.88 | -0.88 | 0.19 | |||
| FCF/share, rub | -1.23 | -0.62 | -0.45 | -0.91 | -0.91 | -0.48 | ||||
| BV/share, rub | 0.09 | -0.51 | 0.51 | 0.61 | 0.62 | 2.05 | ||||
| EBITDA margin, % | ? | -285.1% | -79.9% | -14.9% | -200.0% | -200.0% | 14.4% | |||
| Net margin, % | ? | -311.9% | -148.4% | -50.4% | -204.9% | -204.9% | 13.5% | |||
| FCF yield, % | ? | -25.6% | -12.0% | -7.00% | -12.3% | -18.4% | -8.30% | |||
| ROE, % | ? | -1 406% | 160.4% | -74.4% | -143.1% | -143.1% | 9.44% | |||
| ROA, % | ? | -56.8% | -51.8% | -18.8% | -63.9% | -63.9% | 6.45% | |||
| P/E | ? | -4.00 | -6.21 | -17.0 | -8.44 | -5.64 | 30.1 | |||
| P/FCF | -3.91 | -8.31 | -14.3 | -8.14 | -5.44 | -12.1 | ||||
| P/S | ? | 12.5 | 9.21 | 8.59 | 17.3 | 11.6 | 4.05 | |||
| P/BV | ? | 56.3 | -9.96 | 12.7 | 12.1 | 8.06 | 2.84 | |||
| EV/EBITDA | ? | -2.68 | -9.26 | -44.0 | -7.46 | -4.58 | 18.7 | |||
| Debt/EBITDA | 1.70 | 2.27 | 13.7 | 1.19 | 1.19 | -9.41 | ||||
| R&D/CAPEX, % | 3 315% | 4 025% | 12 496% | 15 643% | 15 643% | 12 933% | ||||
| CAPEX/Revenue, % | 9.75% | 3.46% | 0.69% | 1.25% | 1.25% | 0.38% | ||||
| ImmunoGen shareholders | ||||||||||
